Type 2 Diabetes Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with Type 2 diabetes, based on 1985 World Health Organization standards.
- People who are between 35 and 80 years old.
- People whose vision (with glasses or contact lenses if needed) meets a minimum level of sharpness, equivalent to roughly 20/40 on a standard eye chart.
- People whose glasses prescription falls within a certain range (spherical equivalent of less than 5 diopters).
- People who have a specific stage of diabetic eye disease — either non-proliferative diabetic retinopathy at certain defined severity levels, or mild proliferative diabetic retinopathy meeting specific criteria — where the treating doctor and the patient agree that certain eye treatments can safely be delayed for at least 6 months.
- People who are able to understand and sign a written consent form for the trial.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose retinal thickness in the central area of the eye exceeds a certain measurement (400 µm), unless specific conditions about fluid and retinal shape are met as assessed by the trial's reading centre (confirm with trial site).
- People who show signs of scar tissue or abnormal blood vessel growth on the retina.
- People who have poorly controlled pressure inside the eye, or a specific type of glaucoma caused by abnormal blood vessel growth.
- People who show signs of abnormal blood vessel growth on the iris, or bleeding inside or in front of the retina.
- People who have other blood vessel diseases affecting the eye, such as blockages in the retinal arteries or veins, or a wet form of age-related macular degeneration.
- People who have previously had laser treatment across the retina (panretinal photocoagulation) or injections into the eye.
- People who have had any eye surgery within the 6 months before joining the trial.
- People whose vision inside the eye is significantly obscured by conditions such as a severe cataract, corneal scarring or swelling, or bleeding in the vitreous (the gel inside the eye).
- People whose pupil does not dilate to at least 5 mm.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Inês P Marques, MD PhD, AIBILI - Associação para a Investigação Biomédica e Inovação em Luz e Imagem
Phone: +351239480137
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Changes in capillary skeletonized vessel density (SVD); Changes in capillary perfusion density (PD) using OCTA; Foveal Avascular Zone (FAZ) area; Foveal Avascular Zone (FAZ) perimeter; Foveal Avascular Zone (FAZ) circularity; Changes in retinal ischemic area using UWF FFA; Changes in central retinal thickness (CRT); Changes in central intraretinal fluid; Changes in Disorganisation of Retinal Inner Layers (DRIL); Changes in Disorganisation of Retinal Outer Layers (DROL); Changes in Ganglion Cell Layer (GCL) + Inner Plexiform Layer (IPL) thickness; DRSS severity level; Changes in microaneurysm (...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.